Your browser is no longer supported. Please, upgrade your browser.
ABBV AbbVie Inc. daily Stock Chart
AbbVie Inc.
IndexS&P 500 P/E17.48 EPS (ttm)3.49 Insider Own0.10% Shs Outstand1.65B Perf Week1.35%
Market Cap100.58B Forward P/E10.80 EPS next Y5.65 Insider Trans-27.08% Shs Float1.62B Perf Month-5.44%
Income5.72B PEG1.11 EPS next Q1.20 Inst Own70.10% Short Float2.17% Perf Quarter-4.32%
Sales24.75B P/S4.06 EPS this Y185.20% Inst Trans0.06% Short Ratio5.69 Perf Half Y1.82%
Book/sh3.47 P/B17.57 EPS next Y17.19% ROA10.00% Target Price71.21 Perf Year31.21%
Cash/sh4.85 P/C12.57 EPS next 5Y15.69% ROE119.80% 52W Range43.76 - 67.50 Perf YTD6.92%
Dividend2.28 P/FCF24.54 EPS past 5Y3.50% ROI16.90% 52W High-9.66% Beta1.51
Dividend %3.74% Quick Ratio1.60 Sales past 5Y7.90% Gross Margin78.60% 52W Low39.36% ATR0.99
Employees28000 Current Ratio1.80 Sales Q/Q17.80% Oper. Margin35.00% RSI (14)40.14 Volatility1.48% 1.56%
OptionableYes Debt/Eq6.71 EPS Q/Q17.90% Profit Margin23.10% Rel Volume0.70 Prev Close61.76
ShortableYes LT Debt/Eq6.62 EarningsOct 28 BMO Payout63.30% Avg Volume6.21M Price60.98
Recom2.40 SMA20-2.02% SMA50-3.94% SMA2002.23% Volume4,341,673 Change-1.26%
Oct-18-16Initiated Leerink Partners Mkt Perform $70
Sep-08-16Downgrade JP Morgan Overweight → Neutral
Sep-02-16Initiated Raymond James Outperform $82
Jun-08-16Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-06-16Initiated Societe Generale Sell $47
Mar-15-16Initiated Deutsche Bank Hold $63
Feb-23-16Upgrade Citigroup Neutral → Buy
Dec-01-15Downgrade Barclays Overweight → Equal Weight $73 → $72
Nov-02-15Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-23-15Reiterated UBS Buy $81 → $78
Sep-28-15Upgrade Citigroup Sell → Neutral
Jul-22-15Initiated Sun Trust Rbsn Humphrey Buy
Jun-17-15Initiated Piper Jaffray Overweight
Jun-08-15Reiterated Jefferies Buy $86 → $90
May-28-15Resumed Morgan Stanley Equal-Weight $72
May-27-15Resumed JP Morgan Overweight $75
Jan-06-15Reiterated UBS Buy $72 → $76
Nov-26-14Reiterated Argus Buy $65 → $85
Nov-14-14Initiated Deutsche Bank Buy $80
Jul-28-14Upgrade UBS Neutral → Buy $57 → $67
Oct-21-16 03:00PM  NBIX: AbbVie Presents Positive Phase 3 Data for Elagolix in Endometriosis
Oct-20-16 04:41PM  Gilead Sciences: Is the Bar Set Low Enough for a Beat? at Motley Fool
11:25AM  AbbVie: Encouraging Results From Elagolix Study
10:52AM  3 Healthcare Stocks That Are Looking Cheap at Motley Fool
10:21AM  Can Biogen (BIIB) Keep the Earnings Streak Alive in Q3?
Oct-19-16 01:19PM  Drug Wars: California Vote Could Limit Price Hikes at Investopedia
11:01AM  AbbVie Leukemia Drug Clears European Hurdle (ABBV) at Investopedia
09:54AM  Better Buy: AbbVie Inc. vs. Johnson & Johnson at Motley Fool
09:00AM  AbbVie Announces Positive Pivotal Phase 3 Data Demonstrating Investigational Medicine Elagolix Reduces Menstrual and Non-Menstrual Pelvic Pain Associated with Endometriosis at the American Society for Reproductive Medicine Scientific Congre PR Newswire
06:15AM  Encouraging Signs From AbbVie
Oct-18-16 06:21AM  Coverage initiated on AbbVie by Leerink Partners
Oct-17-16 12:00PM  Time For Selective Purchases of Health-Care Stocks
09:24AM  Celgene to Present Phase Ib Data on Crohn's Disease Drug
07:49AM  Get Paid While You Wait: 3 Top Dividend Stocks in Big Pharma at Motley Fool
Oct-16-16 11:16AM  Why Biotech Investors Are Terrified of the Upcoming Elections at Motley Fool
Oct-14-16 05:47PM  Roche, AbbVie: Venclyxto Receives Positive Opinion From Committee
04:07PM  ABBVIE INC. Files SEC form 8-K, Change in Directors or Principal Officers
07:23AM  EMA committee conditionally approves AbbVie leukaemia drug Reuters
Oct-13-16 04:28PM  Watch Out, AbbVie: Johnson & Johnson Is Nipping at Your Heels at Motley Fool
10:40AM  Top 5 Jefferies Big Pharma Stock Picks for Q4 at 24/7 Wall St.
08:06AM  Which Healthcare Company Is the Best Dividend Stock? at Motley Fool
Oct-12-16 01:27PM  How GILD Plans to Battle through Impending HIV Patent Cliff
07:35AM  Major Pharma Short Sellers Grow More Selective at 24/7 Wall St.
Oct-10-16 04:12PM  Tesaro Bolts On Ovarian Cancer Win Vs. AstraZeneca, AbbVie
11:04AM  Whats Driving Gileads Liver Disease Drug Portfolio?
09:20AM  Repros' Secondary Hypogonadism Drug under Review in EU
08:04AM  Whats New with Gilead Sciences?
08:00AM  AbbVie to Host Third-Quarter Earnings Conference Call PR Newswire
12:57AM  Why Large Stocks Wake Up at This Time of Year at The Wall Street Journal
Oct-09-16 11:52PM  Why Now May be the Time to Buy Large-Cap Stocks at The Wall Street Journal
08:37AM  4 Stocks To Buy For Big October Dividend Hikes at Forbes
Oct-08-16 08:34AM  This money manager has uncovered dividend stocks trading at attractive prices at MarketWatch
04:33AM  Tesaro's ovarian cancer drug benefits all patients in study
02:15AM  Tesaro ovarian cancer drug shows broad benefits in study
Oct-07-16 05:30PM  AbbVie and JNJ, BeiGene Presents First Clinical Data for New Cancer Treatment
04:35PM  Pharma Leader AbbVie's Earnings Growth Excels In Dividend Screen
11:27AM  AbbVie, Inc. : ABBV-US: Dividend Analysis : July 15th, 2016 (record date) : By the numbers : October 7, 2016
10:36AM  Pfizer to Sell Hospira Infusion Unit to ICU Medical for $1B
Oct-06-16 12:58PM  Gilead, AbbVie, Merck Face 'Black-Box Warning'
09:50AM  Big Pharma and Top Biotechs Highlight Jefferies Stocks to Buy Now at 24/7 Wall St.
08:00AM  AbbVie Presents Pivotal Phase 3 Data on Investigational Treatment Elagolix and Research on the Economic Burden of Endometriosis at the 72nd American Society for Reproductive Medicine Scientific Congress PR Newswire
07:23AM  These 5 Big Stocks Are Breaking Out in October
Oct-05-16 10:17AM  FDA Warns on Hepatitis C Drugs at The Wall Street Journal
10:04AM  How Much Return Could Gilead Offer in the Next Year?
09:26AM  This Looks to Be Johnson & Johnson's Next Blockbuster Drug at Motley Fool
Oct-03-16 04:06PM  AbbVie Receives FDA Ranking for Hepatitis C Therapy
10:25AM  AbbVie: HCV Regimen Obtains Breakthrough Therapy Status
05:08AM  These 5 rock-solid dividend stocks yield 3% or more at MarketWatch
Oct-02-16 05:00AM  Big Pharma vs Big Pharma in court battles over biosimilar drugs Reuters
Oct-01-16 12:13PM  Morphosys moves closer to getting first antibody drug on market Reuters
02:00AM  J&J psoriasis drug tops placebo, Humira in late stage study
Sep-30-16 07:04PM  Understanding Mercks Business Segments and Their Revenue Trends
01:03PM  3 Cheap Growth Stocks You Can Buy Right Now at Motley Fool
10:05AM  Which Products Were Key Contributors to Pfizers Revenue Growth?
08:25AM  SunTrust Has Large Cap Dividend Pharma Stocks to Buy Now at 24/7 Wall St.
08:00AM  AbbVie's Investigational HCV Regimen Receives U.S. FDA Breakthrough Therapy Designation PR Newswire
Sep-29-16 10:32PM  AbbVie Expands Operation in Singapore (ABBV) at Investopedia
09:07AM  How Oncology Could Move the Needle for Johnson & Johnson's Stock at Motley Fool
Sep-28-16 10:00PM  AbbVie Opens First Phase of its Global Manufacturing Facility in Singapore to Support the Growth of its Pipeline PR Newswire
05:51PM  Bristol-Myers, Nektar Tie-Up for Opdivo/NKTR-214 Combo
03:55PM  Better Buy: Johnson & Johnson vs. AbbVie at Motley Fool
02:26PM  Gilead Sciences Stock Downgraded: 3 Things You Need to Know at Motley Fool
01:08PM  Stock Research Reports for Amazon, Boeing & MasterCard
01:03PM  FDA Approval of Amjevita Need Not Worry AbbVie Shareholders
09:18AM  Momenta to Regain Rights to Humira Biosimilar from Shire
04:21AM  AbbVie and Eisai Obtain Additional Approval for New Indication of Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA in the Treatment of non-infectious Uveitis ACN Newswire
Sep-27-16 08:32PM  Amgen's Biosimilar Gets FDA Approval (AMGN, ABBV) at Investopedia
04:28PM  Gilead 'Paralyzed' On Likely Hepatitis C Share Loss To AbbVie, Merck
10:39AM  AbbVie, Inc. Value Analysis (NYSE:ABBV) : September 27, 2016
10:14AM  AbbVie (ABBV) Files sNDA for Blood Cancer Drug Imbruvica
07:40AM  Major Pharma Continues to See Rising Tide in Short Interest at 24/7 Wall St.
Sep-26-16 04:03PM  Wall Street Sells Off on Worries Over Clinton-Trump Showdown
02:38PM  Stocks Fall Ahead of Clinton-Trump Debate, Crude Rallies
02:20PM  As Humira Alternative Gets FDA Approval, Is Abbvie in Trouble?
11:04AM  Whats the Upside Potential for Gilead?
10:10AM  Stock Market News for September 26, 2016
09:00AM  AbbVie Showcases Commitment to Research and Innovation in Dermatology at the 25th European Academy of Dermatology and Venereology Congress PR Newswire
08:52AM  AbbVie, Inc. breached its 50 day moving average in a Bearish Manner : ABBV-US : September 26, 2016
08:46AM  AbbVie (ABBV) HCV Combination Drug Positive in Phase IIIb
08:35AM  Jefferies Makes Huge New Stock Addition to Franchise Picks List at 24/7 Wall St.
07:00AM  AbbVie Announces Submission of a Supplemental New Drug Application for Ibrutinib (IMBRUVICA®) for Treatment of Marginal Zone Lymphoma PR Newswire
06:49AM  Amgen's Biosimilar of Abbvie's Humira Gets FDA Approval
Sep-23-16 07:42PM  FDA Approves Amgen's Biosimilar Version of Humira at The Wall Street Journal
06:22PM  FDA approves lower-cost alternative to biotech drug Humira
05:50PM  U.S. FDA approves Amgen's copy of AbbVie arthritis drug Humira Reuters
04:44PM  U.S. FDA approves Amgen's cheaper copy of arthritis drug Humira
01:04PM  Why Analysts Expect Gileads Revenue to Fall in 2016 and 2017
06:05AM  3 Dividend Investing Tips That Could Earn You Thousands at Motley Fool
04:00AM  AbbVie Presents Data on Eight-Week Treatment of VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) in Patients with Genotype 1b Chronic Hepatitis C PR Newswire
Sep-22-16 06:32PM  3 Top Dividend Stocks for Your Roth IRA at Motley Fool
03:00PM  AbbVie Is Gaining Traction -- Here's How to Trade It From Here
10:48AM  The Pros and Cons of Buying Gilead Sciences Stock at Motley Fool
Sep-21-16 01:00PM  Trend Channel Buying Opportunity in These Stocks (ABBV, RTN) at Investopedia
07:30AM  [$$] Thiel Backs Biotech Anew as Compass Therapeutics Gets $50M at The Wall Street Journal
Sep-20-16 05:25PM  Apple, General Electric, Microsoft Top Q2 In Stock Buybacks
05:20PM  AbbVie Joins BioArctic in Fight Against Parkinson's Disease
02:32PM  AbbVie (ABBV) Stock Gains on BioArctic Parkinson's Collaboration
08:20AM  4 Jefferies Large Cap Franchise Picks That Also Pay Solid Dividends at 24/7 Wall St.
03:48AM  Karolinska Development portfolio company BioArctic enters into Collaboration with AbbVie for Parkinson's Disease Research GlobeNewswire
Sep-19-16 04:04PM  How Valeant Plans to Its Fix Dermatology Portfolio
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for adults with genotype 1 chronic hepatitis, including those with compensated cirrhosis. It also provides Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent respiratory syncytial virus infection in high risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, and endometriosis and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; TriCor, Trilipix, and Niaspan to treat metabolic conditions characterized by high cholesterol and/or high triglycerides; and Zemplar to treat secondary hyperparathyroidism. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has strategic collaboration with C2N Diagnostics; Calico Life Sciences LLC; Infinity Pharmaceuticals, Inc.; Ablynx NV; Galapagos NV; and Alvine Pharmaceuticals, Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schumacher Laura JExecutive Vice PresidentSep 07Sale65.0050,0003,250,000144,138Sep 09 05:38 PM
Schumacher Laura JExecutive Vice PresidentJun 24Option Exercise27.62186,1065,140,971380,244Jun 28 05:47 PM
Schumacher Laura JExecutive Vice PresidentJun 24Sale60.03186,10611,171,173194,138Jun 28 05:47 PM
GONZALEZ RICHARD AChairman of the Board and CEOJun 02Sale63.82285,95318,249,712338,421Jun 03 05:26 PM
GONZALEZ RICHARD AChairman of the Board and CEOMay 11Sale63.8039,0002,488,200338,421May 13 05:11 PM
HURWICH THOMAS A.VP, ControllerMay 10Option Exercise27.296,000163,74068,204May 12 05:44 PM
HURWICH THOMAS A.VP, ControllerMay 10Sale63.596,000381,54162,204May 12 05:44 PM
ALBAN CARLOSEVP, Commercial OperationsMay 10Sale63.5247,4383,013,262149,444May 12 05:39 PM
Schumacher Laura JExecutive Vice PresidentMar 08Sale56.0925,0001,402,341194,138Mar 08 05:23 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 05Option Exercise22.943,40077,9985,143Feb 09 05:13 PM